Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1

Molecular Diversity
Priya MahajanAmit Nargotra

Abstract

The traditional method of drug discovery process has been surpassed by a rational approach where computer-aided drug designing plays a vital role in the identification of leads from large compound databases. Further, natural products have an important role in drug discovery as these have been the source of most active ingredients of medicines. Herein, in silico structure- and ligand-based approaches have been applied to screen in-house IIIM natural product repository for Akt1 (serine/threonine protein kinases) which is a well-known therapeutic target for cancer due to its overexpression and preventing the cells from undergoing apoptosis. Combined ligand-based and structure-based strategies were applied on to the existing library comprising of about 700 pure natural products, and the compounds identified from screening were biologically evaluated for Akt1 inhibition using Akt1 kinase activity assay. Fourteen promising compounds showed significant inhibition at 500 nM through in vitro screening, and from them, eight were new for Akt1 inhibition. Through the MD studies of Akt1 with the most active compound IN00145, it was inferred that Lys179, Glu191, Glu228, Ala230, Glu234 and Asp292 are the important amino acid residues which pr...Continue Reading

References

Sep 30, 1999·Environmental Health Perspectives·S Dev
Jun 28, 2002·Journal of Chemical Information and Computer Sciences·Xuebin QiaoXiaojie Xu
Nov 26, 2003·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·S Böckmann, B Nebe
Mar 5, 2004·Journal of Medicinal Chemistry·Christine B BreitenlechnerBirgit Masjost
Apr 28, 2005·Current Topics in Medicinal Chemistry·Stanley F BarnettCraig W Lindsley
Jun 16, 2005·Molecular Cancer Therapeutics·Yan LuoVincent L Giranda
Aug 13, 2005·Advances in Cancer Research·Alfonso BellacosaJoseph Robert Testa
Nov 17, 2005·Oncogene·Chandra C Kumar, Vincent Madison
Apr 11, 2006·Bioorganic & Medicinal Chemistry Letters·Gui-Dong ZhuVincent L Giranda
Apr 29, 2006·Bioorganic & Medicinal Chemistry Letters·Gui-Dong ZhuVincent L Giranda
Jun 27, 2006·The AAPS Journal·Young-Won ChinA Douglas Kinghorn
Jan 30, 2007·Bioorganic & Medicinal Chemistry·Gui-Dong ZhuVincent L Giranda
Apr 25, 2007·Journal of Medicinal Chemistry·Gordon SaxtyRobin A Carr
May 6, 2008·Bioorganic & Medicinal Chemistry Letters·Blaise LippaJoel Morris
Sep 11, 2008·Current Drug Metabolism·Avni G DesaiHari K Bhat
Jan 31, 2009·Bioorganic & Medicinal Chemistry Letters·Meagan B RouseDirk A Heerding
Mar 17, 2009·Bioorganic & Medicinal Chemistry Letters·Mark A SeefeldDirk A Heerding
May 13, 2009·Journal of Chemical Information and Modeling·Thomas A Halgren
Sep 19, 2009·Journal of Chemical Information and Modeling·Noeris K SalamWoody Sherman
Feb 9, 2010·Bioorganic & Medicinal Chemistry Letters·Qingping ZengXiaoling Zhang
Feb 9, 2010·Bioorganic & Medicinal Chemistry Letters·Qingping ZengXiaoling Zhang
Apr 9, 2010·Journal of Chemical Information and Modeling·K Shawn WattsJohn C Shelley
May 21, 2010·Journal of Medicinal Chemistry·Kevin D Freeman-CookJoel Morris
Sep 3, 2010·Bioorganic & Medicinal Chemistry Letters·James F BlakeBarbara J Brandhuber
Oct 26, 2010·Bioorganic & Medicinal Chemistry Letters·Josef R BencsikLesley J Murray
Dec 9, 2010·Journal of Natural Products·David G I Kingston
Mar 12, 2011·Bioorganic & Medicinal Chemistry Letters·Nicholas C KallanNicholas J Skelton
Mar 23, 2011·Bioorganic & Medicinal Chemistry Letters·Rui XuNicholas J Skelton
Aug 10, 2011·Bioorganic & Medicinal Chemistry Letters·Kate S AshtonRandall Hungate
Dec 17, 2011·Bioorganic & Medicinal Chemistry Letters·Shaohua ChangKe Ding
Mar 28, 2012·Bioorganic & Medicinal Chemistry Letters·Kenneth D RiceWei Xu
May 10, 2012·Science Signaling·Kui LinBarbara J Brandhuber
Jul 12, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Timothy A YapMichelle D Garrett
Apr 13, 2013·Journal of Computer-aided Molecular Design·G Madhavi SastryWoody Sherman
May 15, 2013·Autophagy·Francois Lamoureux, Amina Zoubeidi
Jun 6, 2014·ACS Medicinal Chemistry Letters·Thuy NguyenKeith C Ellis

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Software Mentioned

SP
PHASE
PAINS Remover
ConfGen
LigPrep
ChemAxon
Schrodinger
CADD
GraphPad prism
OPLS

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.